Laviana Pharma
Balancing Global Strength with Local Speed
Wenting Chen, Co-Founder and CEO
Preclinical Research Services
Preclinical research services help life sciences companies evaluate therapeutic candidates before human clinical studies. With a focus on study design, safety testing, data quality and regulatory readiness, they support stronger development decisions and more reliable research progression.
Solutions
Drug development is evolving—shifting from small-molecule drugs (under 500 molecular weight) to larger (above 1,000), more complex compounds—designed to interact with biological pathways more precisely. Therapeutics like peptides and GLP-1 receptor agonists offer enhanced efficacy and target specificity but bring formulation challenges due to their size, fragility and poor oral bioavailability. These complexities demand advanced delivery systems and specialized handling.
State of Industry
Surging Demand in Preclinical Research in Drug Development
The substantial growth in preclinical research services underscores the increasing sophistication required in drug development among pharmaceutical and biotechnology companies, which face ongoing pressure to expedite the creation of new treatments and therapies. Preclinical research is essential for determining the safety and efficacy of prospective drugs before they transition into clinical trials. As the complexity of drug discovery and development continues to evolve, there is a corresponding reliance on preclinical services to generate the comprehensive data necessary for regulatory approvals and to facilitate successful clinical outcomes.
Deep Dive
Preclinical Research Services for a More Demanding Drug Pipeline
Drug developers now face a tighter preclinical window than prior cycles allowed. Candidate complexity is rising, development capital is being scrutinized earlier and supply-chain planning has moved closer to the start of CMC strategy. For executives acquiring preclinical research services, the decision is no longer limited to outsourcing discrete chemistry tasks. It is a choice about whether a partner can turn uncertain science into a development path that remains credible when the molecule advances, the formulation question becomes harder and regulatory expectations begin to shape every technical decision.
Leadership Perspective
Bristol Myers Squibb
Potential of Cell and Gene Therapy
Kathy Van Sickle, Director, Preclinical ADME and PK, Neuroscience
Kathy Van Sickle is a drug development scientist with 25 years of experience in clinical and non-clinical pharmaceutical research. A Wake Forest University graduate with a B.S. in Chemistry, she contributed to securing FDA approval for Cobenfy, a schizophrenia treatment. Known for expertise in regulatory strategy, pharmacokinetics and leadership, Sickle excels in advancing innovative therapies and fostering highperforming teams, driving meaningful progress in drug development and patient care.
Preclinical Research Services Info
Q1
What Do Top Preclinical Research Services Help Drug Developers Accomplish?
Preclinical research services help drug developers evaluate whether a candidate is scientifically sound, safe enough to advance and practical to develop before human trials begin. Top Preclinical Research Services often support early decision-making through chemistry, formulation, analytical testing, safety assessment and development planning that connects discovery work with later clinical and manufacturing requirements.
Q2
What Services Are Usually Included in Preclinical Research Support?
Preclinical research support may include compound characterization, process research, formulation screening, stability evaluation, analytical method development, toxicology support, pilot-scale preparation and documentation for regulatory planning. Top Preclinical Research Services are valuable when these workstreams are coordinated rather than treated as separate tasks, because early technical choices can influence cost, timelines and clinical readiness.
Q3
Why Is Demand Growing for Preclinical Research Services?
Demand is rising because drug pipelines are becoming more complex, development budgets are being reviewed earlier and sponsors need clearer evidence before advancing candidates. Top Preclinical Research Services help address this pressure by identifying formulation, manufacturability, safety and scale-up concerns sooner, reducing the chance that a promising program faces avoidable delays later in development.
Q4
How Are Leading Preclinical Research Providers Evaluated?
Leading preclinical research providers are typically evaluated on scientific depth, laboratory capability, documentation quality, safety practices, responsiveness and the ability to support programs beyond isolated experiments. Top Preclinical Research Services should also show strong understanding of regulatory expectations, technology transfer needs and how early research decisions can affect clinical, manufacturing and commercial pathways.
Q5
How Do Preclinical Research Services Create Value for Drug Development Teams?
Preclinical research services create value by reducing uncertainty before costly clinical investment begins. They can help drug development teams compare technical routes, avoid rework, control risk, improve data quality and strengthen development continuity. Top Preclinical Research Services are especially important when sponsors need disciplined evidence to support funding decisions, regulatory preparation and faster movement into the next development stage.
Q6
What Role Do Innovation and Expertise Play in Preclinical Research Services?
Innovation and expertise matter because modern drug candidates often involve complex chemistry, sensitive formulations, high-potency handling or specialized analytical needs. Top Preclinical Research Services combine experienced scientific judgment with advanced tools, robust safety systems and practical development thinking. This balance helps teams solve early technical problems while keeping later scale-up, compliance and quality requirements in view.
